Various studies showed remarkable anti-tumor effects in targeting PD-L1 in solid tumors with the engineered humanized antibody MPDL3280A (Atezolizumab), especially when PD-1 was expressed by tumor-infiltrating lymphocytes (TILs). Here, PDCD1 is linked to neoplasm.